ImmunityBio Company

ImmunityBio is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases.

Investors

Technology: Atrificial Vectors and Immune Cells, Cell therapy
Industry: Deep Diagnostics, Public
Headquarters: Culver City, California, United States
Founded Date: 2014-01-01
Employees Number: 101-250
Funding Status: IPO
Investors Number: 2
Total Funding: 389656035
Estimated Revenue: $50M to $100M
Last Funding Date: 2023-02-15
Last Funding Type: Post-IPO Equity

Visit Website
https://twitter.com/immunitybio
Register and Claim Ownership